

OL48

O-antigen variability among clinical isolates of Klebsiella pneumoniae

Jolanta LUKASIEWICZ [1], Daria ARTYSZUK [1], Wojciech JACHYMEK [1], Anna MACIEJEWSKA [1], Marta KASZOWSKA [1]

[1] Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland

jolanta.lukasiewicz@hirszfeld.pl

Klebsiella pneumoniae is a nosocomial pathogen, pointed out by the WHO as "critical" regarding the highly limited options for the treatment of infections.

Lipopolysaccharide (LPS, O-antigen) and capsular polysaccharide (K-antigen) are its virulence factors and surface antigens, determining O- and K-serotypes and encoded by O- or K-loci. They are promising targets for antibody-based therapies (vaccines and passive immunization) as an alternative to antibiotics. To make such immunotherapy effective, knowledge about O/K-antigen structures and distribution among clinical isolates is necessary. *K. pneumoniae O*-antigens seem to have limited variability [1], however the presence of new O-serotypes was indicated by genetic analyses [2].

Twelve nontypeable and drug-resistant clinical isolates of *K. pneumoniae* were analysed for *O*-antigen structure. Isolates were selected based on the lack of homology between isolates' O-loci and reference O-loci for already known O-antigens. Discrepancies for O2 serotyping between Kaptive-based predictions (O2 variant 2 serotype) and the actual phenotype (O2 variant 1) were explained for strains BIDMC 7B and ABC152 (presence of insertion sequences in O-loci) [*3*,*4*]. New O-antigens have been identified for isolates Kp175, Kp231, Kp254. Semi-rough character was found for Kp159 and Kp160 LPS. Isolates Kp164, Kp165, Kp166 were identified as the O4. Additionally O-antigen variability of New Delhi metallo- β -lactamase (NDM)-producing *K. pneumoniae* responsible for a countrywide outbreaks in Poland (2012-2018) is discussed.

This study was supported by the National Science Centre, Poland (grant no. 2018/31/B/NZ7/04002).

Bibliographic references:

E. Vinogradov, E. Frirdich, L. L. MacLean, M. B. Perry, B. O. Petersen, J. Ø. Duus, C. Whitfield (2002), J. Biol. Chem. (277) 25070-25081.
R. Follador, E. Heinz, E. K. Wyres, M. J. Ellington, M. Kowarik, K. E. Holt, N. R. Thomson (2016), Microb. Genom. (2) e000073.
R. R. Wick, E. Heinz, K. E. Holt, K. L. Wyres (2018), J. Clin. Microbiol. (56) e00197.

4. D. Artyszuk, R. Izdebski, A. Maciejewska, K. Kaszowska, A, Herud, V. Szijártó, M. Gniadkowski, J. Lukasiewicz (2020), Int. J. Mo<mark>l. S</mark>

Glycans, pathogens and immunity / Glycans in diseases and therapies